Providence Therapeutics Announces World-First Personalized Pediatric mRNA Cancer Vaccine Trial

2026-02-04 - 13:38

Landmark Australian study opens new possibilities for children with aggressive brain tumors and signals opportunity for Canada and USA. CALGARY, AB and BRISBANE, Australia , Feb. 5, 2026 /PRNewswire/ — Providence Therapeutics, a Canadian clinical-stage mRNA biotechnology company, is supporting a world-first clinical trial evaluating personalized mRNA cancer vaccines for children with advanced and treatment-resistant brain tumors. The PaedNEO-VAX